Introduction {#Sec1}
============

Obstructive sleep apnea (OSA) is a common disorder with an estimated prevalence of 10--50% in men and 3--24% in women \[[@CR1]--[@CR4]\]. OSA is an independent risk factor for coronary artery disease (CAD), and up to 70% of patients with CAD have undiagnosed OSA \[[@CR5]\]. Several studies have shown that OSA is associated with an increased risk for cardiovascular diseases such as myocardial infarction, stroke or death from cardiovascular disease \[[@CR6]--[@CR9]\].

Optical coherence tomography (OCT) and optical frequency domain imaging (OFDI) are intravascular imaging modalities that use reflection of near-infrared light to create images. These methods give images with high resolution of 10--20 µm, which is 10 times higher than that of intravascular ultrasound (IVUS). Recent OCT and OFDI studies have reported plaque rupture, lipid-rich plaques, thinned cap fibroatheroma (TCFA), cholesterol crystals, macrophage accumulation, and microchannels as characteristics of unstable plaque \[[@CR4], [@CR10]--[@CR19]\].

Computed tomography (CT) in patients with OSA has revealed larger coronary plaque burdens and a larger lipid core compared to patients without OSA \[[@CR20], [@CR21]\]. IVUS has shown that patients with OSA have a larger coronary atherosclerotic plaque volume than patients without OSA \[[@CR22]\]. OCT and OFDI are superior to these modalities due to their higher resolution in visualizing in-depth microstructure. In the current study, the association of OSA with features of plaque stability was examined using OFDI in patients undergoing percutaneous coronary intervention (PCI), as the first such study of this association.

Methods {#Sec2}
=======

Sample population {#Sec3}
-----------------

Data were analyzed retrospectively for 50 consecutive patients (37 men, 13 women) aged \> 30 years who underwent OFDI-guided PCI at Hokkaido Cardiovascular Hospital between October 2015 and October 2018. For each participant, polysomnography (PSG) monitoring was performed within 6 months of OFDI-guided PCI. PSG monitoring was conducted in a standardized fashion. Overnight PSG was performed using an SAS-3200 (Nihon Kohden, Tokyo, Japan). A total of 21 lesions were examined in 15 patients with OSA based on an apnea hypopnea index (AHI) ≥ 15, and 49 lesions were examined in 35 patients without OSA (AHI \< 15). The mean ages in the OSA and non--OSA groups were 71.8 ± 10.4 and 69.7 ± 8.9 years, respectively, with no significant difference between the groups. Patients presenting with left main CAD and cardiogenic shock were already excluded from 50 consecutive patients who underwent OFDI-guided PCI. Patients who accepted continuous positive airway pressure therapy (CPAP) as a treatment for OSA were also excluded. The study was approved by the Ethics Committee of Hokkaido Cardiovascular Hospital and was performed in compliance with the Declaration of Helsinki and ethical principles for medical research involving human subjects. All patients gave written informed consent.

Coronary angiography {#Sec4}
====================

Coronary angiograms were analyzed by offline quantitative coronary angiography (GE ver. 5.10.1, Pie Medical Imaging BV. Maastricht, The Netherlands). Reference diameter, minimum lumen diameter, diameter stenosis, and lesion length were measured.

OFDI method and analysis {#Sec5}
========================

An OFDI imaging catheter (FastView™, Terumo Corp., Tokyo, Japan) was advanced using a 0.014-inch guidewire with the help of a 6- or 7-Fr guiding catheter, and the imaging core was placed at a site distal to the lesion. Before PCI, OFDI was performed with continuous flush of contrast media at a rate of 4 mL/s, and the OFDI wire was pulled back at a rate of 20--40 mm/s. OFDI was generally performed without dilation by a balloon catheter, but the lesion was dilated with a small-sized balloon if the OFDI catheter could not pass through the lesion because of severe stenosis. For patients with acute coronary syndrome (ACS) without spontaneous recanalization, aspiration thrombectomy was performed prior to OFDI. The plaque morphology of culprit lesions was studied. Other lesions in the same epicardial artery with \> 50% stenosis in angiography were also included in OFDI analysis. After identifying the most stenotic cross-section, the 5-mm proximal and distal cross-sections (total length: 10 mm) were examined. Cross-sectional images were then analyzed every 1 mm and evaluated for the presence of plaque rupture, plaque erosion, luminal thrombus, and categorized into lipid-rich plaque, TCFA, or a lesion with macrophage infiltration, cholesterol crystals, microchannels or calcification. OFDI analysis was conducted by two independent investigators (T.K. and R.K.) who were blinded to the clinical course of each patient. When there was discordance between the investigators, a consensus reading was obtained.

Definitions of OFDI findings {#Sec6}
============================

OFDI analysis revealed the presence of plaque rupture, plaque erosion, intraluminal thrombus, lipid-rich plaque, TCFA, macrophage accumulation, microvessels, and cholesterol crystals in the plaque. Plaque rupture was defined as the presence of fibrous cap discontinuity leading to communication between necrotic tissue and the lumen (Fig. [1](#Fig1){ref-type="fig"}a) \[[@CR23], [@CR24]\]. Plaque erosion was defined as a lesion without fibrous cap disruption and the presence of thrombus \[[@CR25]\]. A thrombus was defined as a well-delineated mass with a high signal attached to the luminal surface or floating within the lumen \[[@CR24]\]. Lipid-rich plaques were defined as lesions with a lipid arc \> 180° (Fig. [1](#Fig1){ref-type="fig"}b) \[[@CR24]\]. The lipid arc was measured within a lipid-rich plaque, and the maximum value was recorded (Fig. [1](#Fig1){ref-type="fig"}b). Lipid-core length was defined as the length of plaque with \> 90° of lipid and was measured on the longitudinal view. The lipid index is the maximum lipid arc multiplied by the lipid-core length \[[@CR26]\]. A cholesterol crystal was defined as a thin, linear region of high signal intensity within the lipid plaque, without backscattering (Fig. [1](#Fig1){ref-type="fig"}c) \[[@CR24]\]. TCFA was defined as a fibrous cap thickness (FCT) \< 65 μm, where FCT is the minimum thickness of a signal-rich layer from the coronary artery lumen to the inner border of the underlying lipid in the culprit lesion (Fig. [1](#Fig1){ref-type="fig"}d) \[[@CR24]\]. Macrophage accumulation was defined as increased signal intensity within the fibrous cap, accompanied by heterogeneous backward shadows (Fig. [1](#Fig1){ref-type="fig"}e), and macrophages were semiquantified based on axial and circumferential distribution, as follows: grade 0, no macrophages; grade 1, localized macrophage accumulation; grade 2, clustered accumulation in \< 1 quadrant; grade 3, clustered accumulation in ≥ 1 and \< 3 quadrants; and grade 4, clustered accumulation in ≥ 3 quadrants (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR24], [@CR27]\]. The range for the macrophage score was 0--40, based on summation of the 0--4 grades across all slices. Microchannels were defined as small vesicular or tubular structures with diameters of 50 to 300 μm within the intima (Fig. [1](#Fig1){ref-type="fig"}f) \[[@CR24]\]. The number of microchannels was also counted at the cross-section with the highest number of microchannels \[[@CR19]\]. Calcification was defined as well-delineated and low backscattered heterogeneous regions \[[@CR24]\]. Spotty calcium deposits were defined as those with length \< 4 mm and maximal arc \< 90°, and deposits not meeting these criteria were classified as large calcium deposits \[[@CR28], [@CR29]\]. Microcalcification was defined as a small microcalcification with a maximal calcium angle \< 22.5° and a maximal calcification length \< 1 mm \[[@CR30]\].Fig. 1Representative plaque images from optical frequency domain imaging (OFDI).**a** Ruptured plaque (white arrow) with fibrous cap discontinuity leading to communication between the lipid core (LC) and lumen. **b** Measurement of the lipid arc for a lipid-rich plaque. The maximum lipid arc was measured within a lipid-rich plaque (yellow lines). **c** A cholesterol crystal was defined as a thin, linear region of high signal intensity within the lipid plaque, without backscattering. **d** Measurement of fibrous cap thickness. The thickness was measured at the thinnest point three times, and the average was taken (white arrows). **e** Macrophage accumulation was defined as increased signal intensity within the fibrous cap, accompanied by heterogeneous backward shadows (arrowheads). **f** Microchannels were defined as small vesicular or tubular structures with diameters of 50--300 μm within the intimaFig. 2Semiquantification of macrophage accumulation in optical frequency domain imaging (OFDI). Representative cross--sectional OFDI images with the following grades: **a** grade 0, no macrophages; **b** grade 1, localized accumulation; **c** grade 2, clustered accumulation in \< 1 quadrant; **d** grade 3, clustered accumulation in ≥ 1 and \< 3 quadrants; and **e** grade 4, clustered accumulation in ≥ 3 quadrants

Statistical analysis {#Sec7}
--------------------

Continuous variables are shown as means ± standard deviation (SD) or median (interquartile range) and categorical variables as counts and percentages. The normality of distributions was assessed by the Kolmogorov--Smirnov test. Between-group differences were examined by Pearson chi-square or Fisher exact test for categorical variables and Student *t* test or Mann--Whitney *U* test for continuous variables, as appropriate. *P* \< 0.05 was considered to be significant. All data were analyzed with SPSS 25.0 (IBM Corp., Armonk, NY).

Results {#Sec8}
=======

Clinical characteristics {#Sec9}
------------------------

The clinical characteristics of the OSA and non--OSA groups are compared in Table [1](#Tab1){ref-type="table"}. The mean AHI was significantly higher in the OSA group (30.9 ± 12.6 vs. 7.2 ± 3.8, *P* \< 0.001). The mean LDL-C did not differ significantly between the groups (107 ± 29 vs. 104 ± 45 mg/dl, *P* = 0.732). All other characteristics, including medications and concomitant diseases, were similar in the two groups. All patients who had statin therapy prior to PCI were treated with strong statin (atorvastatin 10 mg/day, rosuvastatin 2.5--5 mg/day or pitavastatin 2 mg/day).Table 1Baseline characteristics in patients with and without obstructive sleep apneaItemNon-OSA (*n* = 35)OSA (*n* = 15)*P*-valueAge (years)69.7 ± 8.971.8 ± 10.40.480Male27 (77)10 (67)0.493Body mass index23.6 ± 3.223.6 ± 3.30.986Diabetes mellitus11 (31)4 (27)0.736Hypertension23 (66)12 (80)0.502Dyslipidemia29 (83)12 (80)0.810Chronic kidney disease7 (20)4 (27)0.713Current smoker13 (37)4 (27)0.474Apnea hypopnea index7.2 ± 3.830.9 ± 12.6\< 0.001Family history of coronary artery disease4 (11)3 (20)0.415History of PCI or CABG15 (43)5 (33)0.529History of myocardial infarction11 (31)1 (7)0.079History of TIA or cerebral infarction3 (9)00.545History of peripheral artery disease01 (7)0.300Prior statin use11 (31)6 (40)0.558 Duration \<3 months00-- 3--12 months3 (9)2 (13)0.607 ≥12 months8 (23)4 (27)0.942Prior aspirin use15 (43)7 (47)0.804Prior clopidogrel use11 (31)2 (13)0.294Prior ACEI or ARB9 (26)6 (40)0.333Prior calcium channel blocker use12 (34)4 (27)0.746Prior beta blocker use10 (29)4 (27)0.891Prior eicosapentaenoic acid4 (11)1 (7)0.607Prior ezetimibe4 (11)00.302Hemoglobin (g/dl)13.5±1.513.3 ± 2.00.800HbA1c (%)6.4 ± 1.46.2 ± 1.10.662Glucose (mg/dl)140 ± 78144 ± 640.882LDL-C (mg/dl)104 ± 45107 ± 290.732Triglyceride (mg/dl)115 (86)172 (136)0.564HDL-C (mg/dl)49 ± 1250 ± 140.936LDL-C to HDL-C ratio2.2 ± 1.12.3 ± 0.90.660Acute coronary syndrome18 (51)10 (67)0.320ST-elevation myocardial infarction9 (26)6 (40)0.333Non ST-elevation myocardial infarction9 (26)4 (27)0.944Values are mean ± SD or number (%) of observations*PCI* percutaneous coronary intervention, *CABG* coronary artery bypass grafting, *TIA* transient ischemic attack, *ACE*angiotensin-converting enzyme inhibitor, *ARB* angiotensin II receptor blocker

Angiographic findings {#Sec10}
=====================

Plaque location and angiographic data are shown for the two groups in Table [2](#Tab2){ref-type="table"}. The OSA group had a significantly higher stenosis diameter (87.7% ± 14.6% vs. 79.7% ± 15.4%, *P* = 0.044). There were no significant differences in plaque location or in other angiographic data between the two groups.Table 2Angiographic characteristics in patients with and without obstructive sleep apneaItemNon-OSA (*n *= 49)OSA (*n *= 21)*P*-valuePlaque location Left anterior descending artery, *n* (%)19 (39)10 (48)0.491 Left circumflex artery, *n* (%)13 (27)4 (19)0.503 Right coronary artery, *n* (%)17 (35)7 (33)0.912Minimum lesion diameter, mm1.21±0.570.92±0.590.060Reference diameter, mm2.90±0.572.93±0.420.789Lesion length, mm15.2±6.216.8±7.40.372Diameter stenosis, %79.7±15.487.7±14.60.044

Plaque characteristics assessed by OFDI {#Sec11}
=======================================

The results of qualitative and semi-quantitative analysis of OFDI characteristics of the coronary plaques are shown in Table [3](#Tab3){ref-type="table"}. Since the scores of macrophage grading and maximum number of microchannels were not distributed normally, Mann--Whitney *U*-test was used to compare differences between the two groups. Other continuous variables regarding OFDI characteristics were normally distributed. The OSA group had significantly higher prevalences of TCFA (67% vs. 35%, *P* = 0.014) and microchannels (86% vs. 55%, *P* = 0.014), a significantly higher mean lipid index (1392 ± 982 vs. 817 ± 699, *P* = 0.021), macrophage grade (8.4 ± 6.4 vs. 4.8 ± 4.5, *P* = 0.030), and maximum number of microchannels (1.5 ± 1.0 vs. 0.7 ± 0.7, *P* = 0.001), and a significantly lower mean minimum FCT (69.4 ± 28.7 vs. 96.1 ± 51.8 μm, *P* = 0.008) compared to the non--OSA group. AHI was positively correlated with the plaque characteristics of lipid index (*r* = 0.400, *P* \< 0.001, Fig. [3](#Fig3){ref-type="fig"}a), macrophage grade (*r* = 0.453, *P* \< 0.001, Fig. [3](#Fig3){ref-type="fig"}c), and number of microchannels (*r* = 0.431, *P* \< 0.001, Fig. [3](#Fig3){ref-type="fig"}d), inversely correlated with the minimum FCT (*r* = − 0.315, *P* = 0.008; Fig. [3](#Fig3){ref-type="fig"}b), and not significantly correlated with the maximum thickness of calcification (*r* = 0.094, *P* = 0.440; Fig. [3](#Fig3){ref-type="fig"}e).Table 3OFDI characteristics in patients with and without obstructive sleep apneaItemNon-OSA (*n *= 49)OSA (*n *= 21)*P*-valueNumber of subjects3515Number of plaques4921Plaques/subjects1.4±0.51.4±0.60.872Plaque rupture6 (12)4 (19)0.473Plaque erosion6 (12)3 (14)0.815Luminal thrombus12 (24)8 (38)0.248Lipid-rich plaque18 (37)10 (48)0.394 Maximum lipid arc (degrees)155 ± 71184 ± 900.161 Lipid length (mm)4.5 ± 3.16.3 ± 3.50.028 Lipid index817 ± 6991392 ± 9820.021Thin capped fibroatheroma (TCFA)17 (35)14 (67)0.014 Minimum fibrous cap thickness (μm)96.1±51.869.4±28.70.008Macrophage infiltration34 (69)18 (86)0.152 Macrophage grading4.8±4.58.4±6.40.030 Cholesterol crystals18 (37)10 (48)0.394Microchannels27 (55)18 (86)0.014 Maximum number of microchannels0.7±0.71.5±1.00.001Calcification26 (53)16 (76)0.070 Large calcification16 (33)7 (33)0.956 Spotty calcification13 (27)7 (33)0.564 Maximum thickness of calcification426±468449±4140.516 Microcalcification5 (10)6 (29)0.075Fig. 3Relationships of apnea hypopnea index (AHI) with plaque characteristics. AHI was significantly correlated with **a** lipid index (*r* = 0.400, *P* \< 0.001) **b** minimum fibrous cap thickness (*r* = − 0.315, *P* = 0.008) **c** macrophage grade (*r* = 0.453, *P* \< 0.001), and **d** number of microchannels (*r* = 0.431, *P* \< 0.001), but not with **e** maximum thickness of calcification (*r* = 0.094, *P* = 0.440)

Risk factors for higher lipid index, TCFA, macrophage invasion, and microchannels {#Sec12}
=================================================================================

Multiple logistic regression analyses were performed to identify risk factors for higher lipid index, TCFA, macrophage invasion, and microchannels. Because history of PCI or CABG, history of myocardial infarction, prior aspirin use and prior clopidogrel use were correlated with prior statin use, they were excluded from the multiple variable analysis. We similarly excluded LDL-cholesterol (LDL-C) when we entered LDL-C to HDL-cholesterol (HDL-C) ratio in the multiple variable model. In multiple variable analyses, AHI, prior statin use, and glucose concentration were independently associated with a higher lipid index (Table [4](#Tab4){ref-type="table"}); AHI and LDL-cholesterol (LDL-C) to HDL-cholesterol (HDL-C) ratio were associated with TCFA (Table [5](#Tab5){ref-type="table"}); AHI and prior statin use were associated with greater macrophage grading (Table [6](#Tab6){ref-type="table"}); and AHI, hemoglobin level and HDL-C were associated with greater microchannels (Table [7](#Tab7){ref-type="table"}).Table 4Logistic regression analysis of lipid indexAnalysisSingleMultipleOR (95% CI)*p*-valueOR (95% CI)*p*-valueAge (years)0.40 (0.13--1.22)0.106Male1.00 (0.34--2.92)1.000Body mass index2.67 (0.92--7.77)0.072Diabetes mellitus1.00 (0.35--2.82)1.000Hypertension1.93 (0.70--5.32)0.206Dyslipidemia0.56 (0.16--1.93)0.360Chronic kidney disease1.93 (0.62--6.07)0.259Current smoker1.30 (0.47--3.59)0.607Obstructive sleep apnea2.67 (0.92--7.77)0.072Apnea hypopnea index6.30 (1.61--24.7)0.0088.08 (1.70--38.5)0.009Family history of coronary artery disease2.67 (0.63--11.3)0.183History of PCI or CABG0.43 (0.16--1.15)0.092History of myocardial infarction0.25 (0.08--0.80)0.020Prior statin use0.20 (0.07--0.59)0.0040.18 (0.05--0.62)0.007Prior aspirin use0.44 (0.17--1.16)0.096Prior clopidogrel use0.35 (0.12--1.07)0.065Prior ACEI or ARB0.42 (0.14--1.24)0.117Prior calcium channel blocker use0.66 (0.24--1.86)0.435Prior beta blocker use0.77 (0.28--2.11)0.607Prior eicosapentaenoic acid0.36 (0.07--2.02)0.247Prior ezetimibe0.23 (0.02--2.15)0.197Hemoglobin (g/dl)2.36 (0.81--6.93)0.117HbA1c (%)2.67 (0.63--11.3)0.183Glucose (mg/dl)3.63 (1.20--10.9)0.0226.22 (1.62--23.8)0.008LDL-C (mg/dl)2.01 (0.77--5.22)0.152Triglyceride (mg/dl)1.83 (0.61--5.47)0.277HDL-C (mg/dl)0.60 (0.19--1.91)0.385LDL-C to HDL-C ratio2.67 (0.92--7.77)0.072Acute coronary syndrome2.65 (0.99--7.11)0.054ST-elevation myocardial infarction2.18 (0.79--5.96)0.134Non ST-elevation myocardial infarction1.35 (0.46--3.96)0.585*OR* odds ratio, *CI* confidence interval, *PCI* percutaneous coronary intervention, *CABG* coronary artery bypass grafting, *TIA* transient ischemic attack, *ACEI* angiotensin-converting enzyme inhibitor, *ARB* angiotensin II receptor blockerTable 5Logistic regression analysis of TCFAAnalysisSingleMultipleOR (95% CI)*p*-valueOR (95% CI)*p*-valueAge (years)2.21 (0.83--5.89)0.113Male1.35 (0.45--4.02)0.593Body mass index0.51 (0.20--1.34)0.174Diabetes mellitus0.43 (0.14--1.29)0.133Hypertension1.37 (0.50--3.78)0.544Dyslipidemia0.62 (0.19--2.09)0.444Chronic kidney disease1.87 (0.61--5.77)0.276Current smoker1.07 (0.39--2.96)0.894Obstructive sleep apnea3.77 (1.28--11.1)0.016Apnea hypopnea index11.7 (2.37--57.6)0.0037.55 (1.35--42.4)0.022Family history of coronary artery disease0.49 (0.12--2.08)0.333History of PCI or CABG0.39 (0.14--1.05)0.063History of myocardial infarction0.48 (0.16--1.46)0.196Prior statin use0.20 (0.06--0.64)0.0060.46 (0.12--1.68)0.238Prior aspirin use0.87 (0.34--2.23)0.767Prior clopidogrel use0.66 (0.22--1.94)0.446Prior ACEI or ARB0.78 (0.27--2.24)0.648Prior calcium channel blocker use0.92 (0.33--2.58)0.875Prior beta blocker use0.82 (0.29--2.27)0.700Prior eicosapentaenoic acid0.47 (0.09--2.60)0.386Prior ezetimibe0.29 (0.03--2.75)0.282Hemoglobin (g/dl)0.39 (0.10--1.49)0.169HbA1c (%)0.39 (0.14--1.05)0.063Glucose (mg/dl)0.40 (0.13--1.19)0.100LDL-C (mg/dl)3.02 (1.09--8.40)0.033Triglyceride (mg/dl)0.38 (0.14--1.01)0.053HDL-C (mg/dl)0.38 (0.14--1.01)0.053LDL-C to HDL-C ratio7.11 (2.09--24.2)0.0024.53 (1.15--17.8)0.030Acute coronary syndrome1.41 (0.53--3.71)0.492ST-elevation myocardial infarction3.13 (1.12--8.71)0.0291.97 (0.57--6.77)0.284Non ST-elevation myocardial infarction0.39 (0.12--1.23)0.108*OR* odds ratio, *CI* confidence interval, *PCI* percutaneous coronary intervention, *CABG* coronary artery bypass grafting, *TIA* transient ischemic attack, *ACEI* angiotensin-converting enzyme inhibitor, *ARB* angiotensin II receptor blockerTable 6Logistic regression analysis of macrophage infiltrationAnalysisSingleMultipleOR (95% CI)*p*-valueOR (95% CI)*p*-valueAge (years)3.23 (0.93--11.3)0.066Male1.26 (0.43--3.69)0.672Body mass index0.48 (0.15--1.53)0.215Diabetes mellitus1.04 (0.37--2.95)0.940Hypertension1.14 (0.42--3.09)0.804Dyslipidemia0.46 (0.13--1.67)0.237Chronic kidney disease1.11 (0.36--3.41)0.858Current smoker1.75 (0.62--4.94)0.290Obstructive sleep apnea2.08 (0.72--6.05)0.177Apnea hypopnea index7.80(1.61--37.9)0.0115.97 (1.10--32.5)0.039Family history of coronary artery disease2.18 (0.52--9.25)0.289History of PCI or CABG0.32 (0.12--0.85)0.023History of myocardial infarction0.38 (0.13--1.12)0.078Prior statin use0.20 (0.07--0.58)0.0030.23 (0.07--0.73)0.012Prior aspirin use0.19 (0.07--0.52)0.001Prior clopidogrel use0.27 (0.09--0.84)0.024Prior ACEI or ARB0.79 (0.28--2.22)0.649Prior calcium channel blocker use0.68 (0.24--1.90)0.465Prior beta blocker use0.45 (0.16--1.27)0.132Prior eicosapentaenoic acid0.60 (0.12--2.91)0.526Prior ezetimibe1.29 (0.20--8.21)0.791Hemoglobin (g/dl)2.25 (0.78--6.49)0.133HbA1c (%)3.39 (0.65--17.6)0.147Glucose (mg/dl)3.00 (1.08--8.34)0.0352.95 (0.93--9.39)0.066LDL-C (mg/dl)2.32 (0.77--6.95)0.133Triglyceride (mg/dl)0.41 (0.15--1.08)0.071HDL-C (mg/dl)0.60 (0.22--1.64)0.317LDL-C to HDL-C ratio1.93 (0.69--5.44)0.212Acute coronary syndrome1.33 (0.51--3.48)0.557ST-elevation myocardial infarction0.77 (0.29--2.07)0.603Non ST-elevation myocardial infarction2.00 (0.65--6.13)0.225*OR* odds ratio, *CI* confidence interval, *PCI* percutaneous coronary intervention, *CABG* coronary artery bypass grafting, *TIA* transient ischemic attack, *ACEI* angiotensin-converting enzyme inhibitor, *ARB* angiotensin II receptor blocker

###### 

Logistic regression analysis of microchannels

                                              Analysis                                        
  ------------------------------------------- ------------------- ------- ------------------- -------
  Age (years)                                 4.19 (0.50--35.1    0.187                       
  Male                                        0.26 (0.08--0.85)   0.025   0.33 (0.06--1.69)   0.182
  Body mass index                             2.13 (0.61--7.43)   0.234                       
  Diabetes mellitus                           1.52 (0.47--4.88)   0.482                       
  Hypertension                                1.23 (0.38--4.05)   0.728                       
  Dyslipidemia                                0.67 (0.18--2.52)   0.547                       
  Chronic kidney disease                      0.66 (0.16--2.66)   0.558                       
  Current smoker                              0.38 (0.10--1.51)   0.170                       
  Obstructive sleep apnea                     5.46 (1.69--17.6)   0.005                       
  Apnea hypopnea index                        8.04 (2.36--27.3)   0.001   9.44 (1.99--44.9)   0.005
  Family history of coronary artery disease   2.41 (0.59--9.84)   0.220                       
  History of PCI or CABG                      0.99 (0.33--2.99)   0.981                       
  History of myocardial infarction            0.50 (0.13--1.97)   0.318                       
  Prior statin use                            1.48 (0.48--4.57)   0.493                       
  Prior aspirin use                           0.53 (0.17--1.63)   0.525                       
  Prior clopidogrel use                       0.28 (0.06--1.38)   0.118                       
  Prior ACEI or ARB                           1.06 (0.32--3.51)   0.930                       
  Prior calcium channel blocker use           0.42 (0.11--1.64)   0.211                       
  Prior beta blocker use                      0.38 (0.10--1.51)   0.170                       
  Prior eicosapentaenoic acid                 1.28 (0.23--7.29)   0.781                       
  Prior ezetimibe                             0.77 (0.08--7.36)   0.817                       
  Hemoglobin (g/dl)                           0.12 (0.04--0.42)   0.001   0.18 (0.04--0.79)   0.022
  HbA1c (%)                                   1.86 (0.62--5.59)   0.271                       
  Glucose (mg/dl)                             6.32 (0.77--51.9)   0.086                       
  LDL-C (mg/dl)                               1.88 (0.62--5.73)   0.266                       
  Triglyceride (mg/dl)                        0.58 (0.19--1.75)   0.334                       
  HDL-C (mg/dl)                               6.72 (1.77--25.5)   0.005   5.31 (1.03--27.3)   0.046
  LDL-C to HDL-C ratio                        0.33 (0.09--1.13)   0.078                       
  Acute coronary syndrome                     0.68 (0.23--2.05)   0.496                       
  ST-elevation myocardial infarction          0.33 (0.08--1.28)   0.108                       
  Non ST-elevation myocardial infarction      1.86 (0.57--6.09)   0.303                       

*OR* odds ratio, *CI* confidence interval, *PCI* percutaneous coronary intervention, *CABG* coronary artery bypass grafting, *TIA* transient ischemic attack, *ACEI* angiotensin-converting enzyme inhibitor, *ARB* angiotensin II receptor blocker

Correlations among microchannels, macrophage grade, and FCT {#Sec13}
===========================================================

There were significant correlations among microchannels, macrophages and FCT. Macrophage grading was positively correlated with the number of microchannels (*r* = 0.383, *P* = 0.001; Supplemental Fig. 1), and FCT was inversely correlated with the macrophage grade (*r* = − 0.415, *P* \< 0.001; Supplemental Fig. 2).

Observer variabilities {#Sec14}
======================

OFDI images were analyzed by two independent observers. The inter-observer reliabilities and intra-observer reproducibilities measured by the Pearson coefficient were *r* = 0.90 and 0.91 for lipid index, *r* = 0.92 and 0.94 for minimum FCT, *r* = 0.95 and 0.93 for macrophage grading, and *r* = 0.92 and 0.95 for maximum number of microchannels, respectively.

Discussion {#Sec15}
==========

The main findings in this study were (1) that patients with OSA had a larger lipid burden, thinner fibrous cap, greater macrophage accumulation, and more microchannels compared to those without OSA; (2) lipid index, minimum FCT, macrophage accumulation and microchannels were positively or inversely correlated with AHI; and (3) in patients undergoing PCI, AHI, prior statin use and glucose concentration were predictors of lipid index; AHI and LDL-C to HDL-C ratio were predictors of TCFA; AHI and prior statin use were predictors of macrophage grading; and AHI, hemoglobin and HDL-C were predictors of greater microchannels. To the best of our knowledge, this study is the first in depth comparison of coronary artery plaques in patients with and without OSA, with analysis of correlations of AHI with characteristics of unstable plaque using OFDI in patients who underwent PCI. These observations improve understanding of the pathophysiology of OSA, and may have important implications for management of patients with OSA presenting with CAD.

Comparison with previous studies {#Sec16}
================================

Our results are concordant with OFDI data from previous studies, with microchannels, macrophage accumulation, and TCFA found in 37--60%, 30--74%, and 11--34% of patients who underwent PCI, respectively \[[@CR31]--[@CR33]\]. FCT measured by OCT was significantly lower in plaques with positive remodeling and in low-attenuation plaques on CT angiography, compared with two-feature--negative plaques (76 ± 24 vs. 192 ± 49 μm, *P* \< 0.001) \[[@CR34]\].

Lipid-rich plaque {#Sec17}
=================

A large lipid core is an important contributor to plaque rupture through mechanically increasing the tension of the fibrous cap covering the lipid core, leading to disruption \[[@CR35]\]. In patients with OSA, intermittent hypoxia (IH) during sleep can increase oxidative stress, leading to oxidative modification of lipoproteins and other molecules \[[@CR36]--[@CR38]\]. These oxidized particles cause endothelial surface injury and promote accumulation of cholesterol in atherosclerotic plaque \[[@CR39], [@CR40]\]. CT studies have shown larger coronary plaque burdens and a larger lipid core in non--culprit lesions of patients with OSA compared to those in patients without OSA \[[@CR20], [@CR21]\], which is consistent with our data (Table [3](#Tab3){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}A).

TCFA and FCT {#Sec18}
============

Previous reports have shown that a thin fibrous cap is one of the most important features of unstable plaque in coronary and carotid artery \[[@CR41]--[@CR43]\]. Since matrix metalloproteinases (MMPs) released by macrophages induce thinning of fibrous caps of atherosclerotic plaques through collagen breakdown \[[@CR44]\], more macrophage accumulation in the fibrous cap might lead to a thinner fibrous cap (Supplemental Fig. 2). Therefore, more macrophage accumulation in the plaque might contribute to a higher prevalence of TCFA and a lower FCT in patients with OSA (Table [3](#Tab3){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}b).

Macrophage accumulation {#Sec19}
=======================

In a murine model of OSA, IH during sleep caused recruitment of more macrophages to the aortic wall \[[@CR45], [@CR46]\], and IH during sleep for 6 weeks led to a significant increase in the percentage of macrophages in the aortic wall (6.4% ± 0.3% vs. 8.1% ± 0.3%, *P* = 0.003) \[[@CR46]\]. Macrophages are thought to be extravasated from intraplaque microvessels into plaque tissue \[[@CR47]\]. The number of microchannels in the plaque was weakly, but positively, correlated with the macrophage grade (Supplemental Fig. 1). Therefore, more intraplaque microvessels and direct invasion from the lumen of coronary arteries might contribute to greater macrophage accumulation in patients with OSA (Table [3](#Tab3){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}c).

Microchannels {#Sec20}
=============

Serum concentrations of vascular endothelial growth factor (VEGF) and endothelin-1, which have important roles in angiogenesis, are increased in patients with OSA \[[@CR48], [@CR49]\]. Oxidative stress due to hypoxia in these patients induces endothelial dysfunction, leading to endothelial-derived microparticle (MP) formation \[[@CR50]\]. MPs are small plasma membrane vesicles with diameters of about 0.05--1.00 μm that are released by plasma membranes of cells such as leukocytes, platelets, endothelial cells, erythrocytes and smooth muscle cells in response to damage \[[@CR51]\]. Ayers et al. showed that the concentrations of platelet- and leukocyte-derived MPs were elevated in patients with OSA \[[@CR52]\], and Tual-Chalot et al. found that MPs from patients with OSA induced an increase of angiogenesis through VEGF- and endothelin-1-mediated pathways \[[@CR49]\]. These mechanisms might explain the finding of more microchannels in patients with OSA and CAD (Table [3](#Tab3){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}d).

Unstable plaque in OSA and clinical perspectives {#Sec21}
================================================

Several studies have shown that OSA might cause or accelerate atherosclerosis \[[@CR53], [@CR54]\]. In this study, multiple regression analysis showed that AHI is independently correlated with features of unstable plaque (Table [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"}, [7](#Tab7){ref-type="table"}). These results support the hypothesis that OSA plays an important role in development of atherosclerotic plaque and plaque instability. However, in the Sleep Apnea Cardiovascular Endpoints (SAVE) trial, CPAP did not result in a lower incidence of the primary end point than usual care alone \[[@CR55]\]. In this trial, the mean duration of CPAP use was only 3.3 h per night, which might not be sufficient for preventing cardiovascular events. After propensity-score matching, the incidence of a cerebrovascular event was significantly lower in 561 patients who used CPAP for more than 4 h per night, compared to that in the usual-care group (hazard ratio, 0.52, *P* = 0.02) \[[@CR55]\]. Furthermore, there is evidence that treatment of OSA with CPAP improves endothelial function and reduces the risk for cardiovascular events \[[@CR56]\], and a randomized controlled trial showed that CPAP therapy resulted in a significant reduction of carotid intima-media thickness \[[@CR57]\]. Therefore, CPAP therapy and stringent management of other coronary risk factors might be effective for stabilization of unstable plaque and secondary prevention of adverse cardiovascular events in patients with OSA.

Limitations {#Sec22}
===========

The sample size of this retrospective, cross--sectional study conducted at a single medical center was small, and the results require confirmation in a prospective study including a larger number of patients. Second, we could not analyze microchannels of \< 50 μm due to the limit of the device resolution. Third, there is an inherent discrepancy between characteristics assessed by OFDI and actual histopathological findings \[[@CR58]\]. Further analyses using higher resolution OFDI might enable more detailed assessment of intraplaque microstructures in patients undergoing PCI. Fourth, we did not have information on inflammatory biomarkers such as high--sensitivity CRP, ICAM-1 and E-selectin. Fifth, the analysis of the risk factors was done on a per lesion basis although the patient characteristics were analyzed on a per patient basis.

Conclusion {#Sec23}
==========

This OFDI analysis suggests that OSA is associated with plaque instability in patients with CAD. More intensive medical management is required for patients with OSA for stabilization of coronary atherosclerotic plaques.

Electronic supplementary material
=================================

 {#Sec33}

Below is the link to the electronic supplementary material. Supplementary material 1 (TIF 89 kb)Supplementary material 2 (TIF 106 kb)
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